Roche Luohua's Ruxolitinib approved for new indications in China.

On March 13th, according to Roche Pharmaceuticals, the China National Medical Products Administration officially announced the approval of the Gazyva (obinutuzumab), bendamustine, and cisplatin regimen for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not suitable for hematopoietic stem cell transplantation.